2-氨基-5-氯苯甲酰肼 | 5584-15-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-5-氯苯甲酰肼
• 中文别名: (2-氨基-5-氯苯甲酰基)肼
• 英文名称: 2-amino-5-chlorobenzhydrazide
• 英文别名: 2-amino-5-chlorobenzohydrazide；5-Chlor-anthranilsaeure-hydrazid
• CAS: 5584-15-6
• 化学式: C₇H₈ClN₃O
• mdl: MFCD00119043
• 分子量: 185.613
• InChiKey: CYDGREISJRDSDE-UHFFFAOYSA-N

物化性质

• 熔点：
  138-142 °C
• 密度：
  1.5437 (rough estimate)
• 稳定性/保质期：

  在常温常压下，该物质是稳定的。

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.1
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 储存条件：
  密封保存，应储存在阴凉干燥的仓库中。

SDS

Name:	(2-Amino-5-Chlorobenzoyl)hydrazide 98% Material Safety Data Sheet
Synonym:	None known
CAS:	5584-15-6

Section 1 - Chemical Product MSDS Name:(2-Amino-5-Chlorobenzoyl)hydrazide 98% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5584-15-6	(2-Amino-5-Chlorobenzoyl)hydrazide	98	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5584-15-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: off-white
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 139.00 - 141.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble
Specific Gravity/Density:
Molecular Formula: C7H8ClN3O
Molecular Weight: 185.61

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5584-15-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(2-Amino-5-Chlorobenzoyl)hydrazide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 5584-15-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5584-15-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5584-15-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-5-氯苯甲酰肼 在 ammonium hydroxide 、 五氯化磷 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 吡啶 为溶剂， 反应 30.08h， 生成 9-氯-2-(2-呋喃基)-[1,2,4]三唑并[1,5-c]喹唑啉-5-胺
  参考文献：
  名称：

  一系列新型三唑并喹唑啉腺苷拮抗剂的结构活性曲线。

  摘要：

  在寻找苯并二氮杂receptor受体调节剂期间，发现了一种高效的腺苷拮抗剂（CGS 15943）。该化合物定义为规范结构9-氯-2-（2-呋喃基）[1,2,4]三唑并[1,5-c]喹唑啉-5-胺（2a）和9的共振稳定杂化物-氯-2-（2-呋喃基）-5,6-二氢[1,2,4]三唑并[1,5-c]-喹唑啉-5-亚胺（2b）。极性介质中的光谱证据和化学反应性支持胺形式2a作为两个规范结构的主要贡献者。描述了2及其一些类似物的合成以及在四个生物学测试系统中的构效关系。用氢，羟基取代9-氯基 甲氧基或甲氧基使化合物在A1和A2受体上具有可比的结合力，但在豚鼠气管条带中作为2-氯腺苷的拮抗剂的活性要低得多。通常，5-氨基的烷基化导致结合活性的丧失，特别是在A2受体上的结合活性的丧失，以及在气管模型中的活性的完全丧失。2-呋喃基的修饰在所有测试系统中引起明显的活性损失。

  DOI：

  10.1021/jm00400a022
• 作为产物：
  描述：

  5-氯邻氨基苯甲酸乙酯盐酸盐 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以92%的产率得到2-氨基-5-氯苯甲酰肼
  参考文献：
  名称：

  一系列新型[1,2,4]三唑并[1,5-c]喹唑啉-5（6H）-的合成及对苯二氮杂的结合活性。

  摘要：

  对与2-芳基吡唑并[4,3-c]喹啉-3（5H）-ones相关的三环杂环的研究，对苯二氮卓（BZ）受体具有高亲和力的结构导致了2-苯基-[1， 2,4] triazolo [1,5-c] quinazolin-5（6H）-one，一种对BZ受体具有4 nM结合亲和力的化合物。制备类似物以评估2-取代基和环取代在修饰活性中的重要性。设计了几种新颖的合成路线来制备目标化合物，包括从蒽腈和酰肼开始的两步合成。在该系列筛选的34种化合物中，在大鼠模型中发现3种化合物是有效的BZ拮抗剂。前导化合物9-氯-2-（2-氟苯基）[1,2,4]三唑并[1,5-c]喹唑啉-5（6H）-一（CGS 16228），

  DOI：

  10.1021/jm00105a044

文献信息

• Iodine-catalyzed synthesis of 5H-phthalazino[1,2-b]quinazoline and isoindolo[2,1-a]quinazoline derivatives via a chemoselective reaction of 2-aminobenzohydrazide and 2-formylbenzoic acid in ionic liquids
  作者：Rong-Zhang Jin、Wen-Ting Zhang、Yu-Jing Zhou、Xiang-Shan Wang

  DOI：10.1016/j.tetlet.2016.04.101

  日期：2016.6

  A chemoselective reaction of 2-aminobenzohydrazides and 2-formylbenzoic acid is described for the synthesis of 5H-phthalazino[1,2-b]quinazoline and isoindolo[2,1-a]quinazoline derivatives in ionic liquids catalyzed by iodine. It is found that the type of the products depends on the steric effect in the reactant of 2-aminobenzohydrazides.

  2- aminobenzohydrazides和2-甲酰基苯甲酸甲化学选择性反应进行5的合成所述ħ -phthalazino [1,2 b ]喹唑啉和异吲哚基[2,1-一个在由碘催化的离子液体]喹唑啉衍生物。发现产物的类型取决于2-氨基苯并肼的反应物中的空间效应。
• Iodine-catalyzed synthesis of fused tetracyclic pyridazino[6,1-b]pyrrolo[1,2-a]quinazolin-9(1H)-one derivatives via a tandem reaction
  作者：Wen-Ting Zhang、Wen-Wen Qiang、Chang-Sheng Yao、Xiang-Shan Wang

  DOI：10.1016/j.tet.2016.03.018

  日期：2016.4

  presence of excess NaHCO3 is described. This is a tandem reaction to construct three new rings and a chiral quaternary carbon center in one-pot procedure. Two possible pathways in the formation of the second heterocycle are proposed, and they are confirmed by the key intermediates of pyrrolo[1,2-a]quinazolin-5(1H)-ones which are selectively obtained via controlling the ratio of base.

  通过2-氨基苯甲酰肼与1,7-二氯庚烷反应合成哒嗪并[6,1- b ]吡咯并[1,2 - a ]喹唑啉-9（1 H）-一衍生物的简便且通用的方法描述了在过量的NaHCO 3存在下由碘催化的-4--1 。这是一种串联反应，只需一锅法即可构建三个新的环和一个手性季碳中心。提出了形成第二个杂环的两个可能途径，并通过吡咯并[1,2 - a ]喹唑啉-5（1 H）-的关键中间体证实，这些中间体是通过控制碱的比例选择性地获得的。
• Synthesis of Diverse Azolo[<i>c</i>]quinazolines by Palladium(II)- Catalyzed Aerobic Oxidative Insertion of Isocyanides
  作者：Tjøstil Vlaar、Lisa Bensch、Jasper Kraakman、Christophe M. L. Vande Velde、Bert U. W. Maes、Romano V. A. Orru、Eelco Ruijter

  DOI：10.1002/adsc.201301129

  日期：2014.4.14

  We report the palladium(II)‐catalyzed aerobic oxidative coupling of isocyanides with various (2‐aminophenyl)azoles using air as the stoichiometric oxidant. A diverse range of medicinally valuable azolo[c]quinazolines was obtained by this new approach.

  我们报告了使用空气作为化学计量氧化剂，钯（II）催化的异氰酸酯与各种（2-氨基苯基）唑类的好氧氧化偶联。通过这种新方法，获得了多种医学上有价值的氮杂[ c ]喹唑啉。
• Synthesis and Evaluation of Adenosine Antagonist Activity of a Series of [1,2,4]Triazolo[1,5-c]quinazolines
  作者：Carmen Balo、Carmen López、José Manuel Brea、Franco Fernánde、Olga Caamaño

  DOI：10.1248/cpb.55.372

  日期：——

  series of [1,2,4]triazolo[1,5-c]quinazolines were prepared in satisfactory yields by reaction of some derivatives of 2-aminobenzohydrazide with several hydrochlorides of aromatic amidines, and their binding affinities for the recombinant human adenosine A2A and A2B receptors were determined. None of the new compounds showed noteworthy affinity for these receptors, though a very high affinity for the A2A

  通过2-氨基苯甲酰肼的某些衍生物与几种芳香族hydro盐酸盐的反应及其对重组人腺苷A2A的结合亲和力，以令人满意的收率制备了一系列[1,2,4]三唑并[1,5-c]喹唑啉确定了A2B受体。新化合物均未显示出对这些受体的显着亲和力，尽管对A2A受体的亲和力非常高，因此对其中一种合成的化合物显示出很高的A2A / A2B选择性。
• [EN] ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS<br/>[FR] COMPOSÉS ACTIVATEURS DU RÉCEPTEUR D'ARYL HYDROCARBONE (AHR) EN TANT QU'AGENTS THÉRAPEUTIQUES CONTRE LE CANCER
  申请人：BROAD INST INC

  公开号：WO2020102506A1

  公开（公告）日：2020-05-22

  The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of FOXA1 and/or FOXA1 gene targets, such as certain breast, liver and/or prostate cancers, including luminal and/or ER-positive forms of breast cancer. Three previously identified adenosine receptor antagonists, CGS-15943, MRS-1220 and SCH-58261, as well as furan ring moiety-possessing derivatives of CGS-15943 are specifically provided for killing cancer cells in a manner that appears to involve activation of the aryl hydrocarbon receptor (AHR) by such compounds. The instant disclosure therefore provides for selecting and/or administering CGS-15943, MRS-1220, SCH-58261 and/or a furan-possessing derivative of CGS-15943, MRS-1220 and/or SCH-58261 as a therapeutic agent to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided

  本公开涉及与诊断和治疗或预防癌症有关的组合物和方法，特别是涉及表达FOXA1和/或FOXA1基因靶点升高的癌症，例如某些乳腺癌、肝癌和/或前列腺癌，包括乳腺癌的分泌性和/或ER阳性形式。已经确定的三种腺苷受体拮抗剂，CGS-15943、MRS-1220和SCH-58261，以及CGS-15943的呋喃环基团衍生物，专门用于以似乎涉及通过这些化合物激活芳香烃受体（AHR）来杀灭癌细胞。因此，本公开提供选择和/或施用CGS-15943、MRS-1220、SCH-58261和/或CGS-15943的呋喃基团衍生物，MRS-1220和/或SCH-58261作为靶向癌细胞和/或患有或有发展癌症风险的受试者的治疗剂的方法。还提供了包括这些化合物的治疗方法和组合物。